Cargando…

Intraocular Pressure Changes After Intravitreal Fluocinolone Acetonide Implant: Results from Four European Countries

INTRODUCTION: The 0.19 mg fluocinolone acetonide (FAc) intravitreal implant delivers a continuous intravitreal corticosteroid dose for the treatment of refractory diabetic macular oedema (DMO). The aim of this study was to assess the impact of an FAc intravitreal implant on intraocular pressure (IOP...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lebrize, Sarah, Arnould, Louis, Bourredjem, Abderrahmane, Busch, Catharina, Rehak, Matus, Massin, Pascale, Barbosa-Breda, Joao, Lupidi, Marco, Mariotti, Cesare, Hamza, Mahmoud, Grise-Dulac, Alice, Gabrielle, Pierre-Henry, Baillif, Stephanie, Creuzot-Garcher, Catherine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9114211/ https://www.ncbi.nlm.nih.gov/pubmed/35426623 http://dx.doi.org/10.1007/s40123-022-00504-z

Ejemplares similares

Management of Patients with Diabetic Macular Edema Switched from Dexamethasone Intravitreal Implant to Fluocinolone Acetonide Intravitreal Implant
por: Baillif, Stéphanie, et al.
Publicado: (2022)

Real-World Efficacy and Safety of Fluocinolone Acetonide Implant for Diabetic Macular Edema: A Systematic Review
por: Kodjikian, Laurent, et al.
Publicado: (2021)

Outcomes in diabetic macular edema switched directly or after a dexamethasone implant to a fluocinolone acetonide intravitreal implant following anti-VEGF treatment
por: Rehak, Matus, et al.
Publicado: (2019)

Fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema
por: Messenger, Wyatt B, et al.
Publicado: (2013)

Intravitreal Fluocinolone Acetonide May Decelerate Diabetic Retinal Neurodegeneration
por: Lynch, Stephanie K., et al.
Publicado: (2019)

Intravitreal methotrexate and fluocinolone acetonide implantation for Vogt-Koyanagi-Harada uveitis
por: Park, Jong G., et al.
Publicado: (2020)

Intravitreal 0.19 mg Fluocinolone Acetonide Implant in Non-Infectious Uveitis
por: Hikal, Muaas, et al.
Publicado: (2021)

Intravitreal fluocinolone acetonide implant (ILUVIEN®) for diabetic macular oedema: a literature review
por: Massa, Horace, et al.
Publicado: (2018)

Sustained Control of Serpiginous Choroiditis with the Fluocinolone Acetonide 0.18 mg Intravitreal Implant
por: Siddiqui, Yousuf, et al.
Publicado: (2022)

Scleral fixation of fluocinolone acetonide implant()
por: Tabandeh, Homayoun, et al.
Publicado: (2020)

Changes in intraocular pressure after intravitreal fluocinolone acetonide (ILUVIEN): real-world experience in three European countries
por: Chakravarthy, Usha, et al.
Publicado: (2019)

Fluocinolone acetonide intravitreal sustained release device – a new addition to the armamentarium of uveitic management
por: Brumm, Matthew V, et al.
Publicado: (2007)

Post-cataract outcomes in patients with noninfectious posterior uveitis treated with the fluocinolone acetonide intravitreal implant
por: Sheppard, John D, et al.
Publicado: (2012)

Intravitreal Fluocinolone Acetonide for Diabetic Macular Edema: Long-Term Effect and Structure/Function Correlation
por: Minnella, Angelo Maria, et al.
Publicado: (2022)

Long-Acting Fluocinolone Acetonide Intravitreal Implant for Recurrent Bilateral Non-Infectious Posterior Uveitis
por: Babel, Adrian T, et al.
Publicado: (2022)

Intravitreal Fluocinolone Acetonide Implant (ILUVIEN(®)) for the Treatment of Retinal Conditions. A Review of Clinical Studies
por: Mushtaq, Yusuf, et al.
Publicado: (2023)

Efficacy and safety of sustained-delivery fluocinolone acetonide intravitreal implant in patients with chronic diabetic macular edema insufficiently responsive to available therapies: a real-life study
por: Massin, Pascale, et al.
Publicado: (2016)

Long-Term Follow-Up of Patient with Diabetic Macular Edema Receiving Fluocinolone Acetonide Intravitreal Implant
por: Bertelmann, Thomas, et al.
Publicado: (2015)

Anterior migration of intravitreal fluocinolone acetonide (Iluvien®) implant in a pseudophakic eye with intact posterior capsule
por: Alzaabi, Manal, et al.
Publicado: (2020)

Off-Label Use of 0.19 mg Fluocinolone Acetonide Intravitreal Implant: A Systematic Review
por: Ribeiro, Flávio, et al.
Publicado: (2021)

Long-term outcomes of phakic patients with diabetic macular oedema treated with intravitreal fluocinolone acetonide (FAc) implants
por: Yang, Y, et al.
Publicado: (2015)

Intravitreal Fluocinolone Acetonide (ILUVIEN) Implant for the Treatment of Refractory Cystoid Macular Oedema After Retinal Detachment Repair
por: Alfaqawi, Fadi, et al.
Publicado: (2018)

Injectable 0.19-mg fluocinolone acetonide intravitreal implant for the treatment of non-infectious uveitic macular edema
por: Weber, Lea F., et al.
Publicado: (2019)

Iluvien™ (Fluocinolone Acetonide 0.19 mg Intravitreal Implant) in the Treatment of Diabetic Macular Edema: A Review
por: Fusi-Rubiano, William, et al.
Publicado: (2018)

Early adoption of the fluocinolone acetonide (FAc) intravitreal implant in patients with persistent or recurrent diabetic macular edema (DME)
por: McCluskey, Jessica D, et al.
Publicado: (2019)

Biomarkers to Predict the Success of Treatment with the Intravitreal 0.19 mg Fluocinolone Acetonide Implant in Uveitic Macular Edema
por: Kessler, Lucy Joanne, et al.
Publicado: (2022)

Preserflo Microshunt Surgery for Ocular Hypertension following Intravitreal Fluocinolone Acetonide Implant Removal: A Case Report
por: Rezkallah, Amina, et al.
Publicado: (2022)

Real-world experience with 0.2 μg/day fluocinolone acetonide intravitreal implant (ILUVIEN) in the United Kingdom
por: Bailey, C, et al.
Publicado: (2017)

Fluocinolone acetonide intravitreal implant as a therapeutic option for severe Sjögren’s syndrome-related keratopathy: a case report
por: Wasielica-Poslednik, Joanna, et al.
Publicado: (2019)

Correction to: Iluvien™ (Fluocinolone Acetonide 0.19 mg Intravitreal Implant) in the Treatment of Diabetic Macular Edema: A Review
por: Fusi-Rubiano, William, et al.
Publicado: (2020)

Safety and effectiveness of the fluocinolone acetonide intravitreal implant (ILUVIEN): 3-year results from the European IRISS registry study
por: Khoramnia, Ramin, et al.
Publicado: (2023)

Association between the retinal vascular network and retinal nerve fiber layer in the elderly: The Montrachet study
por: Arnould, Louis, et al.
Publicado: (2020)

Optical Coherence Tomography Biomarkers of Inflammation in Diabetic Macular Edema Treated by Fluocinolone Acetonide Intravitreal Drug-Delivery System Implant
por: Arrigo, Alessandro, et al.
Publicado: (2020)

Retinal Morpho-Functional Changes Following 0.19 mg Fluocinolone Acetonide Intravitreal Implant for Chronic Diabetic Macular Edema
por: Minnella, Angelo Maria, et al.
Publicado: (2021)

Non-infectious uveitis affecting the posterior segment treated with fluocinolone acetonide intravitreal implant: 3-year fellow eye analysis
por: Pavesio, Carlos, et al.
Publicado: (2021)

Association between the retinal vascular network with Singapore "I" Vessel Assessment (SIVA) software, cardiovascular history and risk factors in the elderly: The Montrachet study, population-based study
por: Arnould, Louis, et al.
Publicado: (2018)

Fluocinolone acetonide and its potential in the treatment of chronic diabetic macular edema
por: Haritoglou, Christos, et al.
Publicado: (2013)

Polymeric Micelles Enhance Mucosal Contact Time and Deposition of Fluocinolone Acetonide
por: Limsitthichaikoon, Sucharat, et al.
Publicado: (2022)

Long-term management of non-ischemic central retinal vein occlusion with fluocinolone acetonide intravitreal implant 190 μg (ILUVIEN®)
por: Coelho, João, et al.
Publicado: (2019)

Clinical Effectiveness of Intravitreal Fluocinolone Acetonide (FAc) (ILUVIEN™) in Patients with Diabetic Macular Oedema (DMO) Refractory to Prior Therapy: The Manchester Experience
por: Young, James F., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_u176qumr47ski9s0tfj70eaad2